

SPECIALTY GUIDELINE MANAGEMENT

XTANDI (enzalutamide)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Xtandi is indicated for the treatment of patients with:

- A. Castration-resistant prostate cancer (CRPC)
- B. Metastatic castration-sensitive prostate cancer (mCSPC)

All other indications are considered experimental/investigational and are not medically necessary.

II. EXCLUSIONS

Coverage will not be provided if the requested medication is used in combination with a second-generation oral anti-androgen (e.g., apalutamide [Erleada]) or an oral androgen metabolism inhibitor (e.g., abiraterone acetate [Zytiga]).

III. CRITERIA FOR INITIAL APPROVAL

A. Castration-resistant prostate cancer (CRPC)

Authorization of 12 months may be granted to members for the treatment of castration-resistant prostate cancer when the member has had a bilateral orchiectomy or will be using the requested medication in combination with a GnRH analog.

B. Metastatic castration-sensitive prostate cancer (mCSPC)

Authorization of 12 months may be granted to members for the treatment of metastatic castration-sensitive prostate cancer when the member has had a bilateral orchiectomy or will be using the requested medication in combination with a GnRH analog.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III who have not experienced disease progression or an unacceptable toxicity.

V. REFERENCES

1. Xtandi [package insert]. Northbrook, IL: Astellas Pharma US, Inc.; December 2019.
2. The NCCN Drugs & Biologics Compendium™ © 2019 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed July 9, 2019.

Reference number(s)
1933-A

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer (Version 2.2019). <https://www.nccn.org>. Accessed July 9, 2019.